Loading...

Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo

Combination therapy concurrently targeting PD1 and CTLA4 immune checkpoints leads to remarkable anti-tumor effects. While both PD1 and CTLA4 dampen the T cell activation, the in vivo effects of these drugs in humans remain to be clearly defined. In order to better understand biologic effects of ther...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Immunol
Main Authors: Das, Rituparna, Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, Gettinger, Scott N., Kluger, Harriet, Callahan, Margaret, Wolchok, Jedd D, Halaban, Ruth, Dhodapkar, Madhav V., Dhodapkar, Kavita M.
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380504/
https://ncbi.nlm.nih.gov/pubmed/25539810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1401686
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!